ArticlebioRxiv : the preprint server for biology2025
Robust footprinting with sample-specific Tn5 bias correction for bulk and single cell ATAC-seq.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Footprint analysis of assay for transposase-accessible chromatin via sequencing (ATAC-seq) enables base-resolution mapping of regulatory elements but is often underpowered and prone to false positives due to data sparsity and Tn5 transposase cleavage bias. We uncover substantial sample-to-sample variability in Tn5 transposase cleavage bias across samples, revealing a previously underappreciated source of batch effects and highlight the motivations for sample-specific Tn5 bias modeling. We present TraceBIND, a computational framework that corrects sample-specific Tn5 bias and use it to identify TF and nucleosome footprints through a dynamic flanking window statistical scan. Compared to existing approaches, TraceBIND substantially reduces false discoveries, controlling type 1 error while maintaining high sensitivity. Even though TraceBIND is completely unsupervised and does not require training on ChIP-seq data, we used multiple validation analyses to demonstrate that TraceBIND matches the power of supervised methods for detection of known TF binding sites. In scATAC-seq data from aging rat kidney, TraceBIND discovers age-associated dynamic regulatory changes, linking footprint activity to age-associated epigenetic drift. This demonstrates that footprint-informed scATAC-seq analysis reveals rich regulatory signals missed by conventional peak-based approaches.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.